anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
One aspect of the present invention relates to compositions comprising polymers and nanoparticles that form hydrogels useful as lens replacement materials, lens substitute materials, corneal inlays, and intraocular lenses. The hydrogels of the invention can be formed using a polyacrylate, silicone, or dendritic macromolecule. In certain instances, the hydrogels of the invention comprise nanoparticles ranging in diameter from about 0.1 nm to about 100 nm. The nanoparticles are generally dispersed throughout the hydrogel and may be covalently or noncovalently crosslinked. The nanoparticles may be made of a metal, metal oxide, or ceramic. In certain instances, the nanoparticles comprise a ceramic core coated with a layer of silica. Another aspect of the present invention relates to a method of forming a lens composition comprising treating a mixture of a polymerizable dendrimeric compound and nanoparticles with a polymerization agent. Another aspect of the present invention relates to a nanoparticle comprising a core coated with a layer of silica. In certain instances, the core is made of a metal, metal oxide, or ceramic. Another aspect of the invention relates to a kit for forming a lens comprising a polymerizable dendrimeric compound, nanoparticles, and a system for delivering the dendrimeric compound and nanoparticles to the lens bag of a patient.
PCT No. PCT/IT93/00136 Sec. 371 Date Jun. 23, 1995 Sec. 102(e) Date Jun. 23, 1995 PCT Filed Dec. 23, 1993 PCT Pub. No. WO94/14421 PCT Pub. Date Jul. 7, 1994An improved process for preparing controlled release pharmaceutical forms comprises exposing a mixture comprising one or more excipients and one or more active ingredients compatible with each other and with said excipients to mechanical or electromechanical actions for a well established time and within a wide range of frequencies to give tablets, matrices or mono or multilayered films. Said forms can be optionally crushed to give a granulate or powder. Depending on the employed excipient, a delayed or rapid but always controllable release of the active ingredient can be attained.
A UV filtering agent and bioadhesive nanoparticles (BNPs) will comprise the experimental condition in this study. Participants will have 5 sites on their torso where they will have these placed.
Sneezing and coughing are primary symptoms of many respiratory viral infections and allergies. It is generally assumed that sneezing and coughing involve common sensory receptors and molecular neurotransmission mechanisms. Here, we show that the nasal mucosa is innervated by several discrete populations of sensory neurons, but only one population (MrgprC11+MrgprA3-) mediates sneezing responses to a multitude of nasal irritants, allergens, and viruses. Although this population also innervates the trachea, it does not mediate coughing, as revealed by our newly established cough model. Instead, a distinct sensory population (somatostatin [SST+]) mediates coughing but not sneezing, unraveling an unforeseen sensory difference between sneezing and coughing. At the circuit level, sneeze and cough signals are transmitted and modulated by divergent neuropathways. Together, our study reveals the difference in sensory receptors and neurotransmission/modulation mechanisms between sneezing and coughing, offering neuronal drug targets for symptom management in respiratory viral infections and allergies.
It is necessary to monitor both the adherence and blood levels of microbicides in order to gauge its efficacy in a study population. Utilizing an experimental microbicide (tenofovir gel) and an anti-HIV drug (TDF), this study will measure the adherence and acceptability to and blood levels of the two interventions in three separate regimens given to HIV-uninfected women.

The expected duration of participation for each participant is 21 weeks. Study participants will be randomly assigned into one of six study groups, each with a different regimen sequence. Each sequence will consist of three study periods and three wash-out periods. Each study period lasts 6 weeks, followed by a 1 week wash-out period. The regimen assigned for a given study period will include either oral TDF, tenofovir vaginal gel, or both. All participants will be prescribed all three regimens in the order designated by their randomized assignment.

Study visits will occur at Weeks 1, 3, 6, 7, 10, 13, 14, 17, 20, and 21. Medical history, a physical exam, behavioral assessment, and urine, blood, pelvic sample collection, and counseling will occur at all visits. At some study sites rectal swabs may be performed. Counseling will include information regarding contraception, protocol adherence, HIV, HIV/Sexually Transmitted Infection risk reduction, and male condom use. Pharmacokinetic (PK) studies, to be determined by the study site, will occur during all three study periods. These studies may involve additional procedures.
A process of converting cannabidiol (CBD) to Δ8-tetrahydrocannabinol (Δ8-THC) or Δ9-tetrahydrocannabinol (Δ9-THC) can enable mass production of Δ8-THC and/or Δ9-THC, achieve greater yields and higher purity in comparison to previously reported processes while eliminating the use of organic solvent. The resultant hemp-derived Δ8-THC can be mixed with and absorbed by natural extracts, including tea extract, starch, sugar, lecithin, and other emulsifiers. Δ8-THC used in edible, topical and vaping products such as powdered Δ8-THC food ingredients, tablets or pills, suppositories, and vape formulations are disclosed. Further described are beverages and baked goods utilizing or incorporating the tablets or powdered Δ8-THC to create edible products containing an emulsified, tasteless, and odorless dose of Δ8-THC. The disclosure also describes a rectal suppository designed to provide improved comfort of use. A Δ8-THC liquid composition can be use in an electronic cigarette smoking device for pulmonary administration of Δ8-THC, which results in more effective absorption.
BACKGROUND: Post-operative sore throat (POST) has an incidence ranging from 21 to 80%. To prevent the development of POST, several pharmacological measures have been tried. Aim of this study was to compare the efficacy of preoperative zinc, magnesium and budesonide gargles in reducing the incidence and severity of POST in patients who underwent endotracheal intubation for elective surgeries.
METHODS: We conducted a prospective, randomized, double-blind, controlled equivalence trial in 180 patients admitted for elective surgical procedures under general anaesthesia. Patients were randomised into three groups; group Z received 40 mg Zinc, group M received 250 mg Magnesium Sulphate and group B received 200 µg Budesonide in the form of 30 ml tasteless and colourless gargle solutions. Sore throat assessment and haemodynamic recording was done postoperatively at immediate recovery (0 h) and 2, 4, 6, 8, 12 and 24 h post-operatively. POST was graded on a four-point scale (0-3).
RESULTS: POST score was comparable at all recorded time points i.e. 0,2,4,6,8,12 and 24 h. Maximum incidence was seen at 8 h in group B (33.3%) and the minimum incidence was at 24 h in group Z (10%) (p > 0.05). It was found that the incidence of POST was more in the surgeries lasting longer than 2 h in all groups. This difference was found to be statistically significant in Groups M and B. The incidence of POST was found to be comparable between laparoscopic and open procedures.
CONCLUSION: Magnesium, zinc and budesonide have an equivocal effect in the prevention of POST at different time points. The incidence of sore throat increases significantly in surgeries lasting more than two hours if magnesium or budesonide have been used as premedicant. Duration of surgery is an independent predictor for POST.
TRIAL REGISTRATION: CTRI/2021/05/033741 Date-24/05/2021(Clinical Trial Registry of India).
Device for applying or maintaining nitrite and/or nitrate cpds. (I) on a patient's skin comprises a porous layer (3) arranged between the skin (2) and at least the major portion of (I) being applied. Pref. a layer (4) acting as source of (I) is provided above the porous layer, esp. in galenical form such as ointment or suspension in an absorbant medium. The porous layer pref. consists of perforated, porous or microporous film and opt. a covering layer (6) which is impermeable to (I) and opt. also to air, is provided on the outside of the device. Pref. materials for the porous layer are polyamide fleece, perforated PVC film, viscose, acetate silk, cellulose-polyamide, cotton, polyurethane, cellulose and synthetic silk, and the outer cover is pref. PVC, polyethylene or lacquered and/or impregnated cotton. The devices are used in treatment of heart disorders, esp. to alleviate angina pectoris as a prophylactic against infarct. The duration of activity of (I) is increased and high initial serum concs. are prevented, so side-effects (nitrate headache' and skin irritation) are minimised.
Many Veterans returning from Iraq and Afghanistan experience problems with drinking. There are treatments for alcohol use disorders that can be very helpful, but sometimes it can be hard for Veterans to find or participate in the treatments. This can be because of the amount of time the treatments take and the long distance to places where substance abuse treatments are offered. For Veterans who live in rural areas, these types of issues can pose even bigger problems. To address these issues, new types of treatments and ways of delivering care are being studied.

We have developed a mobile application that will be accessed through the use of a mobile device such as an ipod. The application will contain an application dedicated to the treatment of substance abuse disorders. This application will provide the coping skills and educational information to aide in helping with problems associated with drinking alcohol.
Patients with DM1 were asked to complete a questionnaire to rate a 25-item activity scale (DM1-Activ) and the Myasthenia Gravis Activity of Daily Life scale (MG-ADL) to rate their level of functional burden. For the DM1-Activ a score of 40 alludes no impairment and a score of 0 indicates the highest functional burden of physical activity. This scale has proven to be practical, reliable and valid. For the MG-ADL the total score ranges from 0 to 24, a score of 0 denotes no and 24 the highest functional burden. It should be noted that this scale is not adjusted for DM1. The rationale was to gain information about muscle fatigue and consequently the neuromuscular junction.
Incontinence-associated dermatitis (IAD) is one of the most serious complications in older people with incontinence. Controlling urine property in absorbent pads could be effective for preventing IAD caused by bacterial urine. However, no animal model has been established to evaluate their effectiveness. This study aimed to induce IAD-like skin changes using absorbent pads containing bacterial urine and to confirm their pathophysiology in rats. Hairless Wistar Yagi rats were divided into the bacteria-containing urine (BU) and the bacteria-free urine (U) groups. A 10-h-attachment of absorbent pads containing artificial urine with/without bacteria to the skin pretreated with sodium lauryl sulfate was performed repeatedly for 5 days. Macroscopic findings and skin barrier function were examined every day, and histological changes, inflammatory responses and bacterial quantification in tissue samples were examined on Day 5. The BU group exhibited significant skin redness from Day 3, significant elevation of transepidermal water loss from Day 1, and histological changes, including significantly thickened epidermis, abnormal keratinocyte differentiation and erythrocyte leakage. Inflammation, confirmed by higher myeloperoxidase-positive cells, elevated tumour necrosis factor-α expression, and vascular endothelial damage, indicated by CD31 and pentraxin 3-positive cells, were observed in the BU group. The bacterial quantification showed no significant difference between the groups. IAD-like skin changes including histological changes and inflammation were suggested to be caused by urine properties altered by bacteria. This study proposed a new animal model for evaluating the effectiveness of absorbent pads in controlling the urine properties of bacterial urine on preventing IAD.
The invention provides a helicobacter pylori vaccine recombinant protein antigen TonB, the amino acid sequence of which is shown as SEQ ID NO. 1. The invention also provides a nucleic acid, a recombinant protein antigen TonB for encoding the helicobacter pylori vaccine. The nucleic acid sequence is shown as SEQ ID NO. 2. The helicobacter pylori vaccine recombinant protein antigen TonB provided by the invention has the advantages of soluble expression, easy purification, high purity and the like, has obvious economic benefit, and animal experiments prove that the helicobacter pylori vaccine recombinant protein antigen TonB effectively stimulates an organism to generate immune response and has good immune protection effect, and can be used as a vaccine candidate component for preventing helicobacter pylori infection.
Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
* Treatment with INCRELEX should be supervised by a physician who is experienced in the diagnosis and management of pediatric patients with short stature associated with severe primary IGF-1 deficiency or with growth hormone gene deletion and who have developed neutralizing antibodies to growth hormone.
  * The dosage of INCRELEX should be individualized for each patient. The recommended starting dose of INCRELEX is 0.04 mg/kg to 0.08 mg/kg of body weight twice daily by subcutaneous injection. If well-tolerated for at least one week, the dose may be increased by 0.04 mg/kg of body weight per dose, to the maximum dose of 0.12 mg/kg of body weight given twice daily [see Warnings and Precautions (5.1 and 5.7)].
  * Preprandial glucose monitoring is recommended at treatment initiation and until a well-tolerated dose is established. If frequent symptoms of hypoglycemia or severe hypoglycemia occur, preprandial glucose monitoring should continue, and glucose monitoring should also occur at the time of event if possible. If hypoglycemia occurs with recommended doses despite adequate food intake, the dose should be reduced. INCRELEX should be administered shortly before or after (± 20 minutes) a meal or snack. If the patient is unable to eat shortly before or after a dose for any reason, that dose of INCRELEX should be withheld.
  * If one or more doses of INCRELEX is missed, do not increase the subsequent doses to make up for omitted doses.
The invention provides a traditional Chinese medicine bath fluid for treating rheumatism and deadlimb and preparing method thereof, involved in the technical field of traditional Chinese medicine preparing. The main raw materials of the traditional Chinese medicine bath fluid are: alyxia sinensis, aristolochiawestlandii hemsl, common achyranthes herb, Indian cloxylon herb, root of veined inula, chloris virata, mountain gyro, steel grass, ziziphora bungana, henbit, heterophyllous wing, psychotria serpens, reticulate millettia, beefwood-like clubmoss herb, garden balsam stem, speranskia tuberculata, passiflora wilsonii hemsl, piper arboricola C. DC. and biondia. The traditional Chinese medicine bath fluid has the advantages of dispelling wind and dampness, relaxing and activating the tendons, antibacterial and deodorization. It is not only well effective for the treatment of rheumatic arthralgia, deadlimb and rheumatic arthritis, but also visibly preventive on psoriasis and beriber. It is safe and non-irritating, worth promoting the use.
INTRODUCTION: Acute respiratory distress syndrome (ARDS) due to severe coronavirus disease 2019 (COVID-19) pneumonia is associated with a high incidence of ventilator-associated pneumonia (VAP). We aimed to evaluate the epidemiology of VAP associated with severe COVID-19 pneumonia.
METHODS: This retrospective observational study recruited patients with COVID-19-associated ARDS admitted to our center from April 1, 2020, to September 30, 2021. The primary outcome was the survival-to-discharge rate. The secondary outcomes were the VAP rate, time to VAP, length of ICU stay, length of ventilator support, and isolated bacteria.
RESULTS: Sixty-eight patients were included in this study; 23 developed VAP. The survival-to-discharge rate was 60.9 % in the VAP group and 84.4 % in the non-VAP group. The median time to VAP onset was 16 days. The median duration of ventilator support and of ICU stay were higher in the VAP group than in the non-VAP group. The VAP rate was 33.8 %. The most common isolated species was Stenotrophomonas maltophilia. On admission, carbapenems were used in a maximum number of cases (75 %). Furthermore, the median body mass index (BMI) was lower and the median sequential organ failure assessment (SOFA) score on admission was higher in the VAP group than in the non-VAP group.
CONCLUSIONS: The survival-to-discharge rate in VAP patients was low. Moreover, VAP patients tended to have long ICU stays, low BMI, and high SOFA scores on admission. Unusually, S. maltophilia was the most common isolated bacteria, which may be related to the frequent use of carbapenems.
The present invention relates to a skin moisturizing cosmetic composition comprising lactic acid bacteria-fermented materials of blueberry and black rice extracts. The lactic acid bacteria-fermented materials of blueberry and black rice extracts according to the present invention reduce the amount of active oxygen produced by UVB stimulation and has inhibitory activities on the expression of MMP-1, which is a collagen degrading enzyme. Thus, it is possible to prevent collagen from being easily decomposed. By promoting the expression of filaggrin, which is a skin moisturizing factor reduced by UVB stimulation, and HAS-1, which is hyaluronic acid synthase. Thus, it is possible to inhibit or reduce the loss of skin moisture due to UV rays. The present invention has an excellent skin moisturizing effect that protects a skin barrier, thereby being useful as a cosmetic composition for moisturizing skin and a food composition for improving skin moisture.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to oncology and concerns treatment and prevention of recurrence and metastasis of tumours containing sex hormone receptors. That is ensured by taking a biopsy material of the tumour to be analysed for androgen and oestrogen receptors to be found. Then the sex hormone level is determined to provide a basis to enable hyperandrogenism to develop by administering a hormonal preparation. Thereafter, the tumour is exposed to a gamma teletherapy in Basic Dose Mode 25 Gy or Basic Dose Mode 40 Gy. Further, if any oestrogen receptors are found in the taken biopsy material, permanent androgenisation is supposed to be achieved, and if observing androgen receptors in the biopsy material, oestrogenisation is required. ^ EFFECT: improved therapeutic effect while inhibiting tumour growth and metastasis up to regress, with reducing number of by-effects and contraindications for the therapy. ^ 3 cl, 1 ex, 1 tbl
Thoracic surgical procedures can often result in postoperative pain. Traditional methods of pain management, such as medication, have limitations in terms of their efficacy and potential side effects. Therefore, there is a need for alternative approaches that can effectively alleviate postoperative pain while minimizing medication use. Virtual reality (VR) technology has gained attention as a potential non-pharmacological intervention for pain management. There is limited research specifically focusing on the use of VR in the context of thoracic surgery. This study is to investigate the effectiveness of VR headsets in reducing postoperative pain intensity among patients after having undergone thoracic surgical procedures. To enhance the objectivity of the investigation, objective parameters alongside subjective assessments of pain will be incorporated. While self-reported measures are valuable, they can be subjective and influenced by individual perception. Therefore, the subjective assessments will be complemented by objective measurements to gain a more comprehensive understanding of the pain experience and its modulation through the VR intervention.
This arm will include early surgical stabilization (within 72 hours of admission) in addition to the usual care received for patients with multiple rib fractures. Usual care will involve pain management.
Four randomized, controlled clinical trials were conducted with GASTROCROM in patients with either cutaneous or systemic mastocytosis; two of which utilized a placebo-controlled crossover design, one utilized an active-controlled (chlorpheniramine plus cimetidine) crossover design, and one utilized a placebo-controlled parallel group design. Due to the rare nature of this disease, only 36 patients qualified for study entry, of whom 32 were considered evaluable. Consequently, formal statistical analyses were not performed. Clinically significant improvement in gastrointestinal symptoms (diarrhea, abdominal pain) were seen in the majority of patients with some improvement also seen for cutaneous manifestations (urticaria, pruritus, flushing) and cognitive function.

The benefit seen with GASTROCROM 200 mg QID was similar to chlorpheniramine (4 mg QID) plus cimetidine (300 mg QID) for both cutaneous and systemic symptoms of mastocytosis. 

Clinical improvement occurred within 2-6 weeks of treatment initiation and persisted for 2-3 weeks after treatment withdrawal. GASTROCROM did not affect urinary histamine levels or peripheral eosinophilia, although neither of these variables appeared to correlate with disease severity. Positive clinical benefits were also reported for 37 of 51 patients who received GASTROCROM in United States and foreign humanitarian programs.